Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Leukemia 5Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Primary Myelofibrosis 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Precancerous Conditions 1Polycythemia Vera 1Multiple Myeloma 1Mastocytosis, Systemic 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Graft vs Host Disease 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory 1Anemia 1

Interventions

luspatercept 4Biopsy 4Lenalidomide 3Epoetin Alfa 3Cyclophosphamide 3Busulfan 3ruxolitinib 2fludarabine 2Filgrastim 2Cyclosporine 2Antilymphocyte Serum 2AP 1903 reagent 2ACE-011 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1vactosertib 1trametinib 1thymoglobulin 1siltuximab 1regorafenib 1ponatinib 1pertuzumab 1pembrolizumab 1palbociclib 1olaparib 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anemia × Thalidomide × Myeloid × Clear all
NCT00053001 2013-06-26

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡